Lorlatinib Superior to Crizotinib for ALK - Positive NSCLC

Interim analysis shows risk for disease progression or death lower for first - line therapy with lorlatinib versus crizotinib
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news